Normocaemic primary hyperparathyroidism in eldery patients. Clinical manifestations and developtment laboratory parameters

Česká verzia

Authors: H. Šiprová; M. Souček; I. Řiháček; K. Šipr
Authors place of work: II. interní klinika LF MU a FN U sv. Anny v Brně
Published in the journal: Geriatrie a Gerontologie 2020, 9, č. 1: 5-8
Category: Original Article/Study

Summary

Primary hyperparathyroidism is the third most prevalent endocrine disease in the Czech Republic (surpassed only by diabetes mellitus and thyroid gland disorders), especially for patients in the sixth and seventh decades of life.A diagnosis can be considered timely only if it happens while the disease is still asymptomatic.High age should not be considered as contraindication for a surgical treatment of primary hyperparathyroidism.

Keywords:

bisphosphonates – primary hyperparathyroidism – hypercalcemia – MIBI – parathyroidectomy – cinacalcet

Zdroje

_Literatura

1. Broulík P, Adámek S, Libánský P, Tvrdoň J. Diagnostika a léčba primární hyperparatyreózy. Interní Med 2007; 3: 130–132.

2. Broulík P. Diferenciální diagnostika hyperkalcemií. Vnitř Lék 2007; 53(7&8): 826–830.

3. Wills MR, Pak CY, Hammond WG, Bartter FC. Normocalcemic primary hyperparathyroidism. Am J Med 1969; 47: 384–391.

4. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after succesful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98(8): 3213–3220.

5. Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: To treat or not to treat? Endocr Pract 2016; 22(3): 294–301.

6. Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ 2012; 19(344):e1013.

7. Čáp J. Léčba primární hyperparatyreózy. Remedia 2010; 20: 96–98.

8. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 1988; 67(6): 1294–1298.

9. Silverberg SJ, Billezikian JP. „Incipient“ Primary Hyperparathyroidism: A „Forme Fruste“ of an Old Disease.J Clin Endocrinol Metab 2003;88(11): 5348–5352.

10. Cusano Ne, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013;16:33–39.

11. YU N, Leese GP, Smith D, et al. The natural history of treated and untreated primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. Q J Med 2011;104: 513–521.

12. Khan AA. Medical management of primary hyperparathyroidism. J Clin Densitom 2013; 16(1): 60–63.

13. Jannasch O, Voigt C, Reschke K, Lippert H, Mroczkowski P. Comparison of outcome between older and younger patients following surgery for primary hyperparathyroidism. Pol Przegl Chir 2013;85(10): 598–604.

14. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis ofparathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006; 140: 874–882.